Analysts predict that Insulet Co. (NASDAQ:PODD) will report $0.03 earnings per share (EPS) for the current quarter, according to Zacks. Eight analysts have made estimates for Insulet’s earnings. The lowest EPS estimate is ($0.04) and the highest is $0.06. Insulet reported earnings of ($0.04) per share in the same quarter last year, which suggests a positive year over year growth rate of 175%. The firm is expected to issue its next quarterly earnings report on Thursday, November 1st.

According to Zacks, analysts expect that Insulet will report full-year earnings of ($0.09) per share for the current year, with EPS estimates ranging from ($0.23) to ($0.01). For the next fiscal year, analysts expect that the firm will report earnings of $0.37 per share, with EPS estimates ranging from $0.13 to $0.61. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Insulet.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.10. Insulet had a negative return on equity of 11.91% and a negative net margin of 3.47%. The firm had revenue of $124.26 million for the quarter, compared to analysts’ expectations of $132.89 million. During the same quarter last year, the firm posted ($0.13) EPS. The company’s revenue was up 13.2% compared to the same quarter last year.

PODD has been the topic of a number of research reports. BidaskClub cut Insulet from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 19th. Zacks Investment Research raised Insulet from a “hold” rating to a “buy” rating and set a $96.00 price objective on the stock in a report on Tuesday, August 7th. Morgan Stanley raised their price objective on Insulet from $87.00 to $96.00 and gave the company an “equal weight” rating in a report on Friday, June 1st. Leerink Swann reissued an “outperform” rating and set a $130.00 price objective on shares of Insulet in a report on Tuesday. Finally, Piper Jaffray Companies raised their price objective on Insulet to $106.00 and gave the company an “overweight” rating in a report on Monday, June 4th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company. Insulet has an average rating of “Buy” and a consensus target price of $95.24.

Shares of NASDAQ:PODD traded up $1.08 on Thursday, hitting $108.13. The company’s stock had a trading volume of 368,400 shares, compared to its average volume of 579,206. Insulet has a 1 year low of $54.55 and a 1 year high of $108.90. The stock has a market cap of $6.37 billion, a P/E ratio of -235.83 and a beta of 1.58. The company has a quick ratio of 5.01, a current ratio of 5.54 and a debt-to-equity ratio of 3.22.

In related news, insider Shacey Petrovic sold 960 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $104.26, for a total transaction of $100,089.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Michael P. Spears sold 5,043 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $86.08, for a total value of $434,101.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,605 shares of company stock worth $586,324. 3.60% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Paloma Partners Management Co grew its position in Insulet by 2,104.4% during the 2nd quarter. Paloma Partners Management Co now owns 168,699 shares of the medical instruments supplier’s stock worth $14,458,000 after acquiring an additional 161,046 shares during the last quarter. New York State Common Retirement Fund grew its position in Insulet by 5.7% during the 1st quarter. New York State Common Retirement Fund now owns 84,496 shares of the medical instruments supplier’s stock worth $7,324,000 after acquiring an additional 4,524 shares during the last quarter. State of Wisconsin Investment Board grew its position in Insulet by 78.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 71,482 shares of the medical instruments supplier’s stock worth $6,126,000 after acquiring an additional 31,482 shares during the last quarter. OppenheimerFunds Inc. grew its position in shares of Insulet by 26.6% in the 2nd quarter. OppenheimerFunds Inc. now owns 791,702 shares of the medical instruments supplier’s stock worth $67,848,000 after buying an additional 166,585 shares during the last quarter. Finally, Eagle Asset Management Inc. bought a new stake in shares of Insulet in the 1st quarter worth approximately $47,002,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Featured Story: Understanding Relative Strength Index

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.